Online Exclusive

  • Communication About Costs of Cancer Care Leads to Better Patient Satisfaction Friday, February 24th, 2017 | , ,

    When physicians communicate with patients about the cost of cancer care, patient satisfaction increases substantially, according to a study published in Cancer. “[Communication about treatment costs] is increasingly important in oncology practice today, as the high costs of cancer care impose tremendous financial burden on patients, their families, and the health-care system,” lead author Ya-Chen […]

  • Eliglustat: Replacing Enzyme Replacement Therapy for Patients With Gaucher Disease Type 1? Friday, February 24th, 2017 | , ,

    Author’s Perspective Lead author Timothy M. Cox, MD: “In this trial of nearly 400 patients with more than 500 patient-years of follow-up [of eliglustat] was safe, tolerable, and resulted in good quality of life. I’ve looked after patients with Gaucher disease for 25 years. Enzyme infusions are effective, but giving infusions – even every two […]

  • Older Adults With Acute Lymphocytic Leukemia Continue to Face Challenges Friday, February 24th, 2017 | , ,

    Author’s Perspective Study co-author Jae Park, MD: “[Older patients with ALL] require a careful evaluation of risks and benefits of each therapeutic option to select the appropriate treatment They should be referred to and evaluated at specialized centers where clinical trials are available and should be encouraged to participate in trials whenever possible. Many challenges […]

  • Outpatient Treatment of Pulmonary Embolism Reduces Rates of Adverse Events Thursday, February 23rd, 2017 | , ,

    The decision to hospitalize patients with acute pulmonary embolism (PE) or treat them as outpatients remains controversial, but according to a study published in the Journal of Thrombosis and Haemostasis, outpatient management of hemodynamically stable PE is associated with a lower rate of adverse events (AEs) compared with hospitalization. “If confirmed [in further studies], [outpatient […]

  • FDA Grants Investigational New Drug Approval for CAR T-Cell Therapy Wednesday, February 22nd, 2017 | , ,

    The U.S. Food and Drug Administration (FDA) approved an Investigational New Drug Application for UCART123, a gene-edited chimeric antigen receptor (CAR) T-cell therapy targeting CD123. As part of this approval, UCART123 will be evaluated in a phase I clinical trial of patients with acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The trial is […]

1 of 40
back to top